The US Food and Drug Administration (FDA) has approved an expanded indication for UCB’s Briviact (brivaracetam) CV as monotherapy or adjunctive therapy for the treatment of partial-onset seizures
Roche has decided to voluntarily withdraw the US accelerated approval for Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) to treat patients with PD-L1-positive metastatic triple-negative breast cancer (mTNBC).
Inovio has secured approval from the Brazilian health regulatory agency, ANVISA, to start the international Phase III part of Phase II/III INNOVATE clinical trial assessing its Covid-19 deoxyribonucleic
Japan has approved AstraZeneca’s Forxiga (dapagliflozin) to treat chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Japanese Ministry of Health, Labour and Welfare
Eli Lilly and Company and Lycia Therapeutics have signed a multi-year collaboration and licensing agreement for the discovery and development of novel lysosomal targeting chimera (LYTAC) degraders. The
Pfizer and its partner BioNTech are seeking approval from the US Food and Drug Administration (FDA) for their booster dose of Covid-19 vaccine, Comirnaty, for individuals aged 16
The European Commission (EC) has approved AbbVie’s Rinvoq (upadacitinib) to treat moderate to severe atopic dermatitis in adults and adolescents aged 12 years and above who are candidates
As per the terms of the deal, Shape is eligible to get an initial payment in addition to development, regulatory and sales milestone payments, potentially more than $3bn in
The US Food and Drug Administration (FDA) has fully approved Pfizer and BioNTech’s biologics license application (BLA) for their Covid-19 vaccine, Comirnaty, for individuals aged 16 years and
The Drugs Controller General of India (DCGI) has granted emergency use authorisation (EUA) for Zydus Cadila’s ZyCoV-D Covid-19 vaccine for adolescents aged 12 years and above. ZyCoV-D, an
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.